EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824
Recruiting
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Apogee Clinical Research, Huntsville, Alabama +161 locations
Conditions: Kidney Disease, Chronic
Register for Updates
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976
Recruiting
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Gender:
ALL
Ages:
Between 30 months and 16 years
Trial Updated:
07/30/2025
Locations: UCSF Benioff Children's Hospital, Oakland, California +24 locations
Conditions: Hypochondroplasia
Register for Updates
COgnitioN With VERiciGuat Evaluation in Heart Failure
NCT06601465
Recruiting
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Calgary, Calgary, Alberta +3 locations
Conditions: Heart Failure, Cognitive Impairment
Register for Updates
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT01760005
Recruiting
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/30/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +37 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
Individualized Fortification of Human Milk for Infants Born ≤ 1250 g (MaxiMoM-InForM)
NCT05308134
Recruiting
Very low birth weight infants have increased nutritional needs. Extra nutrients are added to their human milk feeds to help improve their nutritional status, growth and neurodevelopment. Standard fortification of human milk is routine in most neonatal units in North America, but despite the added nutrients, infants are often discharged from hospitals with poor growth, and their neurodevelopment remains suboptimal. Two individualized fortification methods, target and BUN adjustable, have been pro... Read More
Gender:
ALL
Ages:
21 days and below
Trial Updated:
07/30/2025
Locations: University of Alberta, Edmonton, Alberta +19 locations
Conditions: Very Low Birth Weight Infant
Register for Updates
Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults
NCT06259565
Recruiting
Non-Invasive ventilation (NIV) is a life saving intervention for patients with acute respiratory failure (ARF). Some patients are not able to tolerate the NIV intervention and ultimately fail, requiring the use of invasive mechanical ventilation (IMV) and intubation. Sedation may improve a patient's NIV tolerance. However, this practice has not been adopted by intensivists as the risk of over-sedation resulting in respiratory depression, inability to protect the airway, and inadvertent need for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Fraser Health Authority, Surrey, British Columbia +5 locations
Conditions: Non-Invasive Ventilation
Register for Updates
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Total Dermatology, Birmingham, Alabama +180 locations
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: UCI Medical Center, Orange, California +62 locations
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281
Recruiting
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Gender:
ALL
Ages:
Between 40 years and 100 years
Trial Updated:
07/30/2025
Locations: Novartis Investigative Site, Parkville, Victoria +2 locations
Conditions: Relapsing Multiple Sclerosis
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama (UAB), Birmingham, Alabama +21 locations
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates
Feasibility of Choose to Move Replacement Ready
NCT07069179
Recruiting
Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR/THR) for osteoarthritis (OA). The primary goal of this observational study is to learn if the adapted program, Choose to Move Replacement Ready (CTM-RR), is feasible to deliver to people wi... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/30/2025
Locations: Active Aging Research Team, Robert H. N. Ho Research Centre, Vancouver, British Columbia
Conditions: Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis, Hip, Total Knee Arthroplasty; Total Hip Arthroplasty, Mobility Limitation, Social Isolation or Loneliness, Pain, Implementation Science, Physical Inactivity, Sedentary Behaviors
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Southern California Research Center, Coronado, California +101 locations
Conditions: Primary Biliary Cholangitis, PBC
Register for Updates